PubMed Health⌕ Search

Biomedical subjects

Alison Fox-Robichaud

Publications and source records attributed to Alison Fox-Robichaud.

3 recordsLinked to original sources

Lung development and susceptibility to ventilator-induced lung injury.

RATIONALE: Ventilator-induced lung injury has been predominantly studied in adults. OBJECTIVES: To explore the effects of age and lung development on susceptibility to such injury. METHODS: Ex vivo isolated nonperfused rat lungs (infant, juvenile, and adult) were mechanically ventilated where VT was based on milliliters per kilogram of body weight or as a percentage of the measured total lung capacity (TLC). In vivo anesthetized rats (infant, adult) were mechanically ventilated with pressure-limited VTs. Allocation to ventilation strategy was randomized. MEASUREMENTS: Ex vivo injury was assessed by pressure-volume analysis, reduction in TLC, and histology, and in vivo injury by lung compliance, cytokine production, and wet- to dry-weight ratio. MAIN RESULTS: Ex vivo ventilation (VT 30 ml.kg(-1)) resulted in a significant reduction (36.0 +/- 10.1%, p < 0.05) in TLC in adult but not in infant lungs. Ex vivo ventilation (VT 50% TLC) resulted in a significant reduction in TLC in both adult (27.8 +/- 2.8%) and infant (10.6 +/- 7.0%) lungs, but more so in the adult lungs (p < 0.05); these changes were paralleled by histology and pressure-volume characteristics. After high stretch in vivo ventilation, adult but not infant rats developed lung injury (total lung compliance, wet/dry ratio, tumor necrosis factor alpha). Surface video microscopy demonstrated greater heterogeneity of alveolar distension in ex vivo adult versus infant lungs. CONCLUSION: These data provide ex vivo and in vivo evidence that comparable ventilator settings are significantly more injurious in the adult than infant rat lung, probably reflecting differences in intrinsic susceptibility or inflation pattern.

Animals↗

Drug evaluation: E-5564.

Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by bacterial infection, including septic shock.

Animals↗

Tifacogin (Chiron Corp/Pharmacia Corp).

Tifacogin is a recombinant tissue factor pathway inhibitor (rTFPI) under development by Pharmacia Corp (formerly GD Searle) and Chiron as a potential treatment for sepsis. The product is in phase III trials [406208]. In July 2000, Pharmacia anticipated regulatory filings in 2002 [374505]. Chiron and Searle conducted research on TFPI independently in the early 1990s and entered an agreement to collaborate on the development, manufacturing and marketing of the compound in 1994, granting each other licenses on the patents concerned with TFPI [224098]. Searle (Monsanto Co) first disclosed recombinant TFPI in the associated patent, US-05212091. Unlike natural TFPI, however, it possessed an N-terminal alanine and the expression method using E coli did not always yield entirely homologous protein. A method for expressing genuine TFPI in yeast is disclosed in Chiron's patent WO-09604377. Patents for methods of treating sepsis with TFPI were claimed independently in two patents from Cetus Oncology (Chiron; WO-09324143) and Searle (WO-09325230). The discovery research of TFPI was conducted by Searle in collaboration with Washington University [224098]. Washington University holds two patents, EP-00563023 and WO-09604378, which claim the use of TFPI for the inhibition of microvascular thrombosis and reperfusion injury, respectively. Analysts at Lehman Brothers predicted in December 2001, that there was a 50% probability of the drug making it to market, with peak sales potential of 500 million US dollars in 2003 [434768].

Journal Article↗